Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab ...
Seeking Alpha

Exidavnemab phase 2a study expanded to include MSA patients

STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Nasdaq

Alterity (ATHE) Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

We are thrilled that our Phase 2a study of intranasal foralumab in Multiple System Atrophy has been selected as a late-breaking poster at the 7th World Parkinson Congress,” said Ivor Elrifi, CEO of ...
Medscape

Autonomic Testing May Help Differentiate Multiple System Atrophy From Parkinson Disease

Multiple system atrophy (MSA) is often difficult to distinguish from Parkinson's disease (PD) with autonomic failure, but this is an important distinction for research studies as well as for clinical ...